Drug reference
Essential thrombocythaemia in patients at risk of thrombo-haemorrhagic events who have not responded adequately to other drugs or who cannot tolerate other drugs (initiated under specialist supervision) ▶BY MOUTH ▶Adult: Initially 500 micrograms twice daily, dose to be adjusted at weekly intervals according to response, increased in steps of 500 micrograms daily; usual dose 1–3 mg daily in divided doses (max. per dose 2.5 mg); maximum 10 mg per day
PDF page 1114
Cardiovascular disease—assess cardiac function before and regularly during treatment. concomitant use of drugs that prolong QT-interval—assess cardiac function before and regularly during treatment. risk factors for QT- interval prolongation—assess cardiac function before and regularly during treatment
PDF page 1114
→Appendix 1: anagrelide
PDF page 1114
▶Common or very common Anaemia. arrhythmias. asthenia . diarrhoea. dizziness. fluid retention. gastrointestinal discomfort. gastrointestinal disorders. headaches. nausea . palpitations. skin reactions. vomiting ▶Uncommon Alopecia. appetite decreased. arthralgia. chest pain. chills. confusion. congestive heart failure. constipation. depression. dry mouth. dyspnoea. erectile dysfunction. fever. haemorrhage. hypertension. insomnia. malaise. memory loss. myalgia. nervousness. oedema. pain. pancreatitis. pancytopenia. pneumonia. pulmonary hypertension. respiratory disorders. sensation abnormal. syncope. thrombocytopenia. weight changes ▶Rare or very rare Angina pectoris. cardiomegaly. cardiomyopathy. coordination abnormal. drowsiness. dysarthria. influenza like illness. myocardial infarction. nocturia. pericardial effusion. postural hypotension. renal failure. tinnitus. vasodilation. vision disorders ▶Frequency not known Hepatitis. nephritis tubulointerstitial
PDF page 1114
Effective contraception required during treatment.
PDF page 1114
Manufacturer advises avoid (toxicity in animal studies).
PDF page 1114
Manufacturer advises avoid—present in milk in animal studies.
PDF page 1114
Manufacturer advises use with caution in mild impairment; avoid in moderate-to-severe impairment or if serum transaminases exceed 5 times the upper limit of normal.
PDF page 1114
Manufacturer advises avoid if eGFR less than 50 mL/minute/1.73 m2.
PDF page 1114
▶Monitor full blood count (monitor platelet count every 2 days for 1 week, then weekly until maintenance dose established). ▶Monitor liver function. ▶Monitor serum creatinine. ▶Monitor urea. ▶Monitor electrolytes (including potassium, magnesium and calcium) before and during treatment.
PDF page 1114
There can be variation in the licensing of different medicines containing the same drug. Capsule ▶Anagrelide (Non-proprietary) Anagrelide (as Anagrelide hydrochloride) 500 microgram Anagrelide 500microgram capsules | 100 capsule P £404.57 DT = £402.87 ▶Xagrid (Shire Pharmaceuticals Ltd) Anagrelide (as Anagrelide hydrochloride) 500 microgram Xagrid 500microgram capsules | 100 capsule P £404.57 DT = £402.87 4.2 Thrombocytopenias ANTIHAEMORRHAGICS › THROMBOPOIETIN RECEPTOR AGONISTS
PDF page 1114
Driving and skilled tasks Dizziness may affect performance of skilled tasks (e.g. cycling, driving).
PDF page 1114
Initially 500 micrograms twice daily, dose to be
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1114
